Supplemental Figure 1. Patient disposition

Randomly assigned to treatment (n = 573)

ESK + AD (n = 349)

Full efficacy analysis set* (n = 343)

Discontinued intervention (n = 37)
- Adverse event (n = 16)
- Lack of efficacy (n = 4)
- Lost to follow-up (n = 2)
- Withdrawal by patient (n = 8)
- Protocol violation (n = 2)
- Other (n = 5)

Completed (n = 306)

AD + PBO (n = 224)

Full efficacy analysis set* (n = 222)

Discontinued intervention (n = 16)
- Adverse event (n = 3)
- Lost to follow-up (n = 1)
- Withdrawal by patient (n = 7)
- Protocol violation (n = 2)
- Other (n = 3)

Completed (n = 206)

AD, antidepressant; ESK, esketamine nasal spray; PBO, placebo nasal spray.

The full efficacy analysis set was defined as all randomized patients who received at least one dose of intranasal study medication and one dose of oral antidepressant medication during the double-blind induction phase.